CONDENSED INTERIM STATEMENTS OF COMPREHENSIVE LOSS (Unaudited)
U.S. dollars
|
Six months
ended June 30, |
Six months
ended June 30, | ||||||
| 2023 | 2022 | ||||||
|
U.S. dollars
| |||||||
| Sales | 344,819 | 145,093 | |||||
| Cost of Sales | 194,104 | 128,435 | |||||
| GROSS PROFIT | 150,714 | 16,658 | |||||
| Research and development expenses | 216,181 | 307,396 | |||||
| Selling and marketing expenses | 94,339 | 135,585 | |||||
| General and administrative expenses | 101,877 | 327,415 | |||||
| Prospective initial public offering expenses | 106,754 | 405,777 | |||||
| OPERATING LOSS | 368,436 | 1,159,515 | |||||
| Financing Expenses (Income), net | 64,888 | (211,139 | ) | ||||
| COMPREHENSIVE AND NET LOSS | 433,324 | 948,376 | |||||
| Net loss per ordinary share, basic and diluted | 0.12 | 0.31 | |||||
|
Weighted average number of ordinary shares
outstanding basic and diluted | 3,597,442 | 3,066,785 | |||||
The accompanying notes are an integral part of these condensed interim financial statements.
